Company intelligence / Profile preview
Covalent Bioscience
Houston, Texas, USAcovalentbioscience.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Covalent Bioscience is developing catalytic antibodies that enzymatically destroy disease-causing proteins such as amyloids implicated in Alzheimer’s and other age-related diseases. Their lead program, Alzyme, targets amyloid beta for Alzheimer's. They are also advancing catabody candidates against tau protein and transthyretin amyloid, as well as an electrophilic vaccine for HIV prophylaxis/therapy. The company is at the preclinical/development stage with proof-of-principle data supporting efficacy of their platforms[1][2][3][8].
- Therapeutic areas
- Rare DiseasesNeurologyInfectious Diseases
- Modalities
- Catalytic antibodies (catabodies)Irreversible monoclonal antibodies (iMAbs)Electrophilic vaccines (E-vaccines)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Covalent Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covalent Bioscience.